Cargando…

The presence of PD-1 positive tumor infiltrating lymphocytes in triple negative breast cancers is associated with a favorable outcome of disease

Triple negative breast cancer patients have a poor course of disease not least because of limited treatment options however immunotherapy by targeting the PD-1/PD-L1 checkpoint system is a promising strategy to improve the outcome. Here we systematically investigated the expression of PD-1 on tumor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brockhoff, Gero, Seitz, Stephan, Weber, Florian, Zeman, Florian, Klinkhammer-Schalke, Monika, Ortmann, Olaf, Wege, Anja Kathrin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814205/ https://www.ncbi.nlm.nih.gov/pubmed/29464065 http://dx.doi.org/10.18632/oncotarget.23717

Ejemplares similares

HER4 expression in estrogen receptor-positive breast cancer is associated with decreased sensitivity to tamoxifen treatment and reduced overall survival of postmenopausal women
por: Wege, Anja Kathrin, et al.
Publicado: (2018)

IL-15 enhances the anti-tumor activity of trastuzumab against breast cancer cells but causes fatal side effects in humanized tumor mice (HTM)
por: Wege, Anja K, et al.
Publicado: (2016)

Immune Checkpoint Profiling in Humanized Breast Cancer Mice Revealed Cell-Specific LAG-3/PD-1/TIM-3 Co-Expression and Elevated PD-1/TIM-3 Secretion
por: Bruss, Christina, et al.
Publicado: (2023)

The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients
por: Machleidt, Anna, et al.
Publicado: (2013)

Advanced Immune Cell Profiling by Multiparameter Flow Cytometry in Humanized Patient-Derived Tumor Mice
por: Bruss, Christina, et al.
Publicado: (2022)

Regulation of Programmed Death Ligand 1 (PD-L1) Expression in Breast Cancer Cell Lines In Vitro and in Immunodeficient and Humanized Tumor Mice
por: Rom-Jurek, Eva-Maria, et al.
Publicado: (2018)

CX3CL1 Overexpression Prevents the Formation of Lung Metastases in Trastuzumab-Treated MDA-MB-453-Based Humanized Tumor Mice (HTM)
por: Wege, Anja Kathrin, et al.
Publicado: (2021)

Screening-relevant age threshold of 70 years and older is a stronger determinant for the choice of adjuvant treatment in breast cancer patients than tumor biology
por: Inwald, EC, et al.
Publicado: (2017)

4-IHC classification of breast cancer subtypes in a large cohort of a clinical cancer registry: use in clinical routine for therapeutic decisions and its effect on survival
por: Inwald, Elisabeth Christine, et al.
Publicado: (2015)

Protein kinase C targeting of luminal (T-47D), luminal/HER2-positive (BT474), and triple negative (HCC1806) breast cancer cells in-vitro with AEB071 (Sotrastaurin) is efficient but mediated by subtype specific molecular effects
por: Albert, Veruschka, et al.
Publicado: (2022)

A novel rabbit derived anti-HER2 antibody with pronounced therapeutic effectiveness on HER2-positive breast cancer cells in vitro and in humanized tumor mice (HTM)
por: Wege, Anja Kathrin, et al.
Publicado: (2020)

Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125
por: Seitz, Stephan, et al.
Publicado: (2014)

Presence of HER4 associates with increased sensitivity to Herceptin™ in patients with metastatic breast cancer
por: Sassen, Andrea, et al.
Publicado: (2009)

Does timing of neoadjuvant chemotherapy influence the prognosis in patients with early triple negative breast cancer?
por: Hatzipanagiotou, Maria Eleni, et al.
Publicado: (2023)

Guideline-concordant chemotherapy in patients with hormone receptor-positive and node-positive, early breast cancer leads to better overall and metastases-free survival with limited benefit in elderly patients
por: Taubenhansl, Clara, et al.
Publicado: (2019)

Guideline Concordant Therapy Prolongs Survival in HER2-Positive Breast Cancer Patients: Results from a Large Population-Based Cohort of a Cancer Registry
por: Inwald, E. C., et al.
Publicado: (2014)

Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry
por: Inwald, E. C., et al.
Publicado: (2013)

Differential Expression of PD-L1 during Cell Cycle Progression of Head and Neck Squamous Cell Carcinoma
por: Schulz, Daniela, et al.
Publicado: (2021)

Auswirkungen der COVID-19-Pandemie auf die Inzidenz und Therapie von Krebserkrankungen
por: Inwald, Elisabeth C., et al.
Publicado: (2022)

PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma
por: Martin de la Fuente, Laura, et al.
Publicado: (2020)

Guideline concordant therapy improves survival in high-grade endometrial cancer patients
por: Scharl, Sophia, et al.
Publicado: (2022)

Long-term improvement of quality of life in patients with breast cancer: supporting patient-physician communication by an electronic tool for inpatient and outpatient care
por: Lindberg-Scharf, Patricia, et al.
Publicado: (2021)

Impact of cavity shaving on residual tumor rates in patients with primary invasive carcinoma and carcinoma in situ in breast conserving surgery
por: Fernández-Pacheco, Miriam, et al.
Publicado: (2022)

Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry
por: Inwald, E. C., et al.
Publicado: (2015)

PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma
por: Kim, Ki Hyung, et al.
Publicado: (2019)

Won’t you come on in? How to favor lymphocyte infiltration in tumors
por: Bellone, Matteo, et al.
Publicado: (2012)

Incidence of Anaplastic Large Cell Lymphoma and Breast-Implant-Associated Lymphoma—An Analysis of a Certified Tumor Registry over 17 Years
por: Prantl, Lukas, et al.
Publicado: (2020)

Overexpression of PD-1 and CD39 in tumor-infiltrating lymphocytes compared with peripheral blood lymphocytes in triple-negative breast cancer
por: Zahran, Asmaa M., et al.
Publicado: (2022)

Correction to: PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma
por: Kim, Ki Hyung, et al.
Publicado: (2019)

Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?
por: Incorvaia, Lorena, et al.
Publicado: (2019)

Thrombospondin-1 Silencing Improves Lymphocyte Infiltration in Tumors and Response to Anti-PD-1 in Triple-Negative Breast Cancer
por: Marcheteau, Elie, et al.
Publicado: (2021)

Presence of Adenovirus Species C in Infiltrating Lymphocytes of Human Sarcoma
por: Kosulin, Karin, et al.
Publicado: (2013)

PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma
por: Cao, Jinfeng, et al.
Publicado: (2017)

Target HER four in breast cancer?
por: Brockhoff, Gero
Publicado: (2019)

The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer
por: Mori, Hitomi, et al.
Publicado: (2017)

CD8(+ )lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer
por: Liu, Shuzhen, et al.
Publicado: (2012)

Tumor high endothelial venules (HEVs) predict lymphocyte infiltration and favorable prognosis in breast cancer
por: Martinet, Ludovic, et al.
Publicado: (2012)

Estrogen Actions in Triple-Negative Breast Cancer
por: Treeck, Oliver, et al.
Publicado: (2020)

Prognostic Significance of Lymphocyte Infiltrate Localization in Triple-Negative Breast Cancer
por: Čeprnja, Toni, et al.
Publicado: (2022)

Advances in Tumour-Infiltrating Lymphocytes for Triple-Negative Breast Cancer Management
por: Gorenšek, Rok, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_042kkdoi5da6m7gfkkevca08bd